Journal of Neuro-Oncology

, Volume 105, Issue 3, pp 507–522 | Cite as

Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation

Laboratory Investigation - Human/Animal Tissue

Abstract

Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, is under clinical testing and use in cancer patients, including glioma. However, the molecular mechanisms involved in gefitinib-mediated anticancer effects against glioma remain largely uncharacterized. Gefitinib inhibits cell growth and induces apoptosis in human glioma cells. Gefitinib also induces death of H4 cells with characteristics of the intrinsic apoptotic pathway, including Bax mitochondrial translocation, mitochondrial outer membrane permeabilization, cytochrome c cytosolic release, and caspase-9/caspase-3 activation. The importance of Bax in mediating gefitinib-induced apoptosis was confirmed by the attenuation of apoptosis by Bax siRNA and Bax channel blocker. Gefitinib caused Bad dephosphorylation, particularly in serine-112, and increased its binding preference to Bcl-2 and Bcl-xL. The dephosphorylation of Bad in gefitinib-treated cells was accompanied by reduced intracellular cyclic AMP content and protein kinase A (PKA) activity. Adenylyl cyclase activator forskolin attenuated, but PKA inhibitor H89 augmented, gefitinib-induced Bad dephosphorylation, Bax mitochondrial translocation, caspase-9/caspase-3 activation, and viability loss. Intriguingly, a nonselective protein phosphatase inhibitor okadaic acid alleviated gefitinib-induced alterations, except Bad dephosphorylation. In parallel with the higher basal PKA activity, response of U87 cells to gefitinib treatment was delayed and relatively resistant compared with that of H4 and T98G cells. Inactivation of PKA sensitized H4, T98G, and U87 cells to gefitinib cytotoxicity, Bad dephosphorylation in serine-112, and caspase-9/caspase-3 activation. Our findings suggest the involvement of the Bad/Bax signaling pathway in gefitinib-induced glioma apoptosis. Furthermore, the inactivation of PKA was shown to play a role in triggering the proapoptotic function of Bad.

Keywords

Bad EGFR Gefitinib Glioma 

References

  1. 1.
    Nagane M, Huang HJ, Cavenee WK (1997) Advances in the molecular genetics of gliomas. Curr Opin Oncol 9:215–222PubMedCrossRefGoogle Scholar
  2. 2.
    Soni D, King JA, Kaye AH, Hovens CM (2005) Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathway converge. J Clin Neurosci 12:1–5PubMedCrossRefGoogle Scholar
  3. 3.
    Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD (1990) Effect of epidermal growth factor receptor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50:6039–6044PubMedGoogle Scholar
  4. 4.
    Culy CR, Faulds D (2002) Gefitinib. Drugs 62:2237–2248PubMedCrossRefGoogle Scholar
  5. 5.
    Frampton JE, Easthope SE (2005) Spotlight on gefitinib in non-small cell lung cancer. Am J Pharmacogen 5:133–136CrossRefGoogle Scholar
  6. 6.
    Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  7. 7.
    Chan SK, Gullick WJ, Hill ME (2006) Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 42:17–23PubMedCrossRefGoogle Scholar
  8. 8.
    Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754PubMedGoogle Scholar
  9. 9.
    Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727–7731PubMedCrossRefGoogle Scholar
  10. 10.
    Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89:2965–2969PubMedCrossRefGoogle Scholar
  11. 11.
    Premkumar DR, Arnold B, Pollack IF (2006) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. Mol Carcinog 45:288–301PubMedCrossRefGoogle Scholar
  12. 12.
    Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142PubMedCrossRefGoogle Scholar
  13. 13.
    Jiang Z, Zheng X, Rich KM (2003) Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 84:273–281PubMedCrossRefGoogle Scholar
  14. 14.
    Ichinose M, Liu XH, Hagihara N, Youle RJ (2002) Extracellular Bad fused to toxin transport domains induces apoptosis. Cancer Res 62:1433–1438PubMedGoogle Scholar
  15. 15.
    Cartron PF, Oliver L, Martin S, Moreau C, LeCabellec MT, Jezequel P, Meflah K, Vallette FM (2002) The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients. Hum Mol Genet 11:675–687PubMedCrossRefGoogle Scholar
  16. 16.
    Busser B, Sancey L, Josserand V, Niang C, Favrot MC, Coll JL, Hurbin A (2010) Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. Mol Ther 18:528–535PubMedCrossRefGoogle Scholar
  17. 17.
    Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47–59PubMedCrossRefGoogle Scholar
  18. 18.
    Raung SL, Chen SY, Liao SL, Chen JH, Chen CJ (2007) Japanese encephalitis virus infection stimulates Src tyrosine kinase in neuron/glia. Neurosci Lett 419:263–268PubMedCrossRefGoogle Scholar
  19. 19.
    Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87:99–163PubMedCrossRefGoogle Scholar
  20. 20.
    Das A, Banik NL, Ray SK (2010) Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 116:164–176PubMedCrossRefGoogle Scholar
  21. 21.
    Oka N, Wang L, Mi W, Zhu W, Honjo O, Caldarone CA (2008) Cyclosporine A prevents apoptosis-related mitochondrial dysfunction after neonatal cardioplegic arrest. J Thorac Cardiovasc Surg 135:123–130PubMedCrossRefGoogle Scholar
  22. 22.
    Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ (1999) Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 3:413–422PubMedCrossRefGoogle Scholar
  23. 23.
    Chang GC, Hsu SL, Tsai JR, Liang FP, Lin SY, Sheu GT, Chen CY (2004) Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 68:1453–1464PubMedCrossRefGoogle Scholar
  24. 24.
    Chang GC, Yu CT, Tsai CH, Tsai JR, Chen JC, Wu CC, Wu WJ, Hsu SL (2008) An epidermal growth factor inhibitor, gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur J Pharmacol 600:37–44PubMedCrossRefGoogle Scholar
  25. 25.
    Piechocki MP, Yoo GH, Dibbley SK, Amjad EH, Lonardo F (2006) Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer 119:441–454PubMedCrossRefGoogle Scholar
  26. 26.
    Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC (2007) p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res 67:1163–1169PubMedCrossRefGoogle Scholar
  27. 27.
    Ariyama H, Qin B, Baba E, Tanaka R, Mitsugi K, Harada M, Nakano S (2006) Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 97:724–734PubMedCrossRefGoogle Scholar
  28. 28.
    Cragg MS, Kuroda J, Puthalakath H, Huang DCS, Strasser A (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4:e316CrossRefGoogle Scholar
  29. 29.
    Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J (2009) PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 28:2348–2357PubMedCrossRefGoogle Scholar
  30. 30.
    Danial NN (2009) BAD: undertaker by night, candyman by day. Oncogene 27:553–570Google Scholar
  31. 31.
    Zha J, Harada H, Yang E, Jocker J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619–628PubMedCrossRefGoogle Scholar
  32. 32.
    Chiang CW, Kanies C, Kim KW, Fang WB, Parkhurst C, Xie M, Henry T, Yang E (2003) Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol 23:6350–6362PubMedCrossRefGoogle Scholar
  33. 33.
    Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231–241PubMedCrossRefGoogle Scholar
  34. 34.
    Shimamura A, Ballif BA, Richards SA, Blenis J (2000) Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol 10:127–135PubMedCrossRefGoogle Scholar
  35. 35.
    Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F (2001) Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenesis activity. Clin Cancer Res 7:4156–4163PubMedGoogle Scholar
  36. 36.
    Cohen P, Holmes CFB, Tsukitani Y (1990) Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci 15:98–102PubMedCrossRefGoogle Scholar
  37. 37.
    Xin M, Deng X (2006) Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J Biol Chem 281:18859–18867PubMedCrossRefGoogle Scholar
  38. 38.
    Garibal J, Hollville É, Renouf B, Tétaud C, Wiels J (2010) Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax are necessary for verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells. Cell Signal 22:467–475PubMedCrossRefGoogle Scholar
  39. 39.
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024PubMedCrossRefGoogle Scholar
  40. 40.
    Krex D, Mohr B, Hauses M, Ehninger G, Schackert HK, Schackert G (2001) Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping. J Neurooncol 52:119–128PubMedCrossRefGoogle Scholar
  41. 41.
    Rubenstein M, Shaw M, Mirochnik Y, Slobodskoy L, Glick R, Lichtor T, Chou P, Guinan P (1999) In vivo establishment of T98G human glioblastoma. Methods Find Exp Clin Pharmacol 21:391–393PubMedCrossRefGoogle Scholar
  42. 42.
    Zhang R, Banik NL, Ray SK (2007) Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-κB survival signaling in glioblastoma U87MG cells for induction of apoptosis. Neurochem Res 32:2194–2202PubMedCrossRefGoogle Scholar
  43. 43.
    Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J (2009) EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 8:1751–1760PubMedCrossRefGoogle Scholar
  44. 44.
    Tamura S, Hosoi H, Kuwahara Y, Kikuchi K, Otabe O, Izumi M, Tsuchiya K, Iehara T, Gotoh T, Sugimoto T (2007) Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun 358:226–232PubMedCrossRefGoogle Scholar
  45. 45.
    Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M (2003) Phase I pharmacokinetic trial of the inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922–930PubMedCrossRefGoogle Scholar
  46. 46.
    Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J (2008) Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90:9–17PubMedCrossRefGoogle Scholar
  47. 47.
    Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156–158PubMedCrossRefGoogle Scholar
  48. 48.
    Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G (2008) EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer 123:209–216PubMedCrossRefGoogle Scholar
  49. 49.
    Gustafson DL, Frederick B, Merz AL, Raben D (2008) Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 61:179–188PubMedCrossRefGoogle Scholar
  50. 50.
    Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MCM, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L, Hofer S (2010) Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib—a phase II trial. Mol Cancer Ther. 10(6):1102–1112. doi:10.1158/1535-7163.MCT-11-0048 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  1. 1.Department of Life SciencesNational Chung-Hsing UniversityTaichungTaiwan, ROC
  2. 2.Department of SurgeryFong-Yuan HospitalTaichungTaiwan, ROC
  3. 3.Department of NeurosurgeryTaichung Veterans General HospitalTaichungTaiwan, ROC
  4. 4.Department of Education and ResearchTaichung Veterans General HospitalTaichungTaiwan, ROC
  5. 5.Center for General EducationTunghai UniversityTaichungTaiwan, ROC
  6. 6.Department of Physical TherapyChina Medical UniversityTaichungTaiwan, ROC

Personalised recommendations